CCL3 and neoplasm: Specifically, the engagement of trastuzumab with CD16 induces NK cells to secrete IFN-γ [9] and T cell–recruiting chemokines (IL-8, RANTES, MIP-1α, MIP-1β, MCP-1, MDC) [10, 57], contributing to the modulation of anti-tumor immune responses in the TME.